BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32242461)

  • 1. LncRNAs adjacent to pepsinogen C in gastric diseases and diagnostic efficiencies of joint detection in gastric diseases.
    Liu WJ; Lv Z; Liu JW; Xu Q; Ding HX; Yuan Y
    Future Oncol; 2020 Apr; 16(11):655-663. PubMed ID: 32242461
    [No Abstract]   [Full Text] [Related]  

  • 2. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status.
    Yakut M; Örmeci N; Erdal H; Keskin O; Karayel Z; Tutkak H; Soykan I
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):302-11. PubMed ID: 23137754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNP interactions of PGC with its neighbor lncRNAs enhance the susceptibility to gastric cancer/atrophic gastritis and influence the expression of involved molecules.
    Lv Z; Sun L; Xu Q; Gong Y; Jing J; Dong N; Xing C; Yuan Y
    Cancer Med; 2018 Oct; 7(10):5252-5271. PubMed ID: 30155999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies.
    Cao Q; Ran ZH; Xiao SD
    J Dig Dis; 2007 Feb; 8(1):15-22. PubMed ID: 17261130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study.
    Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Long Q; Flanders WD; Bostick RM; Yuan Y
    Int J Cancer; 2015 Jan; 136(2):425-34. PubMed ID: 24895149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
    Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
    Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum pepsinogens as a gastric cancer and gastritis biomarker in South and Southeast Asian populations.
    Miftahussurur M; Waskito LA; Aftab H; Vilaichone RK; Subsomwong P; Nusi IA; Syam AF; Ratanachu-Ek T; Doohan D; Siregar G; Rezkitha YAA; Fauzia KA; Mahachai V; Yamaoka Y
    PLoS One; 2020; 15(4):e0230064. PubMed ID: 32271765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of IgG1 and IgG2 subclasses to Helicobacter pylori in subjects with chronic inflammation of the gastric mucosa, atrophy and gastric cancer in a country with high Helicobacter pylori infection prevalence.
    Vorobjova T; Ren Z; Dunkley M; Clancy R; Maaroos HI; Labotkin R; Kull K; Uibo R
    APMIS; 2006 May; 114(5):372-80. PubMed ID: 16725014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PGC TagSNP and its interaction with H. pylori and relation with gene expression in susceptibility to gastric carcinogenesis.
    He CY; Sun LP; Xu Q; Liu JW; Jiang JY; Dong NN; Yuan Y
    PLoS One; 2014; 9(12):e115955. PubMed ID: 25551587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum OPN expression for identification of gastric cancer and atrophic gastritis and its influencing factors.
    Chen T; Sun L; He C; Gong Y; Xu Q; Yuan Y
    PLoS One; 2014; 9(12):e114005. PubMed ID: 25479069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic values of serum levels of pepsinogens and gastrin-17 for screening gastritis and gastric cancer in a high risk area in northern Iran.
    Nejadi-Kelarijani F; Roshandel G; Semnani S; Ahmadi A; Faghani B; Besharat S; Akhavan-Tabib A; Amiriani T
    Asian Pac J Cancer Prev; 2014; 15(17):7433-6. PubMed ID: 25227854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis.
    Sitas F; Smallwood R; Jewell D; Millard PR; Newell DG; Meuwissen SG; Moses S; Zwiers A; Forman D
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):119-23. PubMed ID: 8467246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic expression of pepsinogen C in gastric cancer, precancerous lesions and Helicobacter pylori associated gastric diseases.
    Ning PF; Liu HJ; Yuan Y
    World J Gastroenterol; 2005 May; 11(17):2545-8. PubMed ID: 15849808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.
    Bölükbaş C; Bölükbaş FF; Ovünç O; Kiliç G; Dalay R; Güven H; Uras F; Yardimci TK; Sökmen MH; Agan AF; Pişkinpaşa N
    Turk J Gastroenterol; 2006 Sep; 17(3):172-6. PubMed ID: 16941249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pepsinogen C polymorphism on individual susceptibility to gastric cancer and its precancerous conditions in a Northeast Chinese population.
    Sun LP; Guo XL; Zhang Y; Chen W; Bai XL; Liu J; Yuan Y
    J Cancer Res Clin Oncol; 2009 Aug; 135(8):1033-9. PubMed ID: 19132389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of group D patients with negative serum anti-Helicobacter pylori antibody and positive serum pepsinogen test in healthy Koreans.
    Han YM; Chung SJ; Choi JM; Lee C; Kim JS
    J Dig Dis; 2018 Sep; 19(9):529-539. PubMed ID: 30117281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are the serum biomarkers pepsinogen I and II good predictors for the detection of subjects with atrophic gastritis in areas that have different gastric cancer incidence?
    Mohamadkhani A; Darvish Moghaddam S; Salmanroghani H; Allafsghari A; Yazdanbod A; Mirzaei M; Haj-sheykholeslami A; Bashiri J; Sadjadi A; Massarrat S
    Arch Iran Med; 2013 Apr; 16(4):208-12. PubMed ID: 23496362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
    Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area.
    Chapelle N; Petryszyn P; Blin J; Leroy M; Le Berre-Scoul C; Jirka I; Neunlist M; Moussata D; Lamarque D; Olivier R; Tougeron D; Mosnier JF; Matysiak-Budnik T
    Helicobacter; 2020 Oct; 25(5):e12727. PubMed ID: 32700438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.